While the United States lags behind international adoption rates for electronic health records, the federal government's financial reward for "meaningful use" of technology is quickly changing that scenario.
While the United States lags behind international adoption rates for electronic health records, the federal government's financial reward for "meaningful use" of technology is quickly changing that scenario. This increased acceptance of EHR within healthcare organizations has accelerated the pharmaceutical industry's interest in finding a single system that could simultaneously be used for patient care in both the hospital/clinic and clinical trial settings. Since the collection methodologies are similar, a platform that merges EHR principles with the functionality of electronic data capture (EDC) would improve efficiency, eliminate data transcription errors and, ultimately, help speed new drugs to market.
Nextrials' clinical trial management platform, Prism, was one of the first to be used in a merged clinical trial/healthcare setting in real time. There are many benefits for utilizing an interoperable EDC/EHR platform:
- The site uses its own familiar interface and the study coordinator does not need to learn a new program.
- Because the data is taken directly from a patient's record, data collection is faster and source data verification is eliminated.
- Data that is not normally collected within the site's EHR can be collected on eCRFs that are displayed within the EHR interface.
Some of the key, integrated EDC/EHR functionalities now available to researchers using Nextrials' Prism are: patient randomization for faster study starts, flexible form design with conditional fields, start page customization, ad hoc reporting, remote access via mobile devices (iPhone, iPad), integrated safety data management and serious adverse event reporting and inventory management.